case report | Q2782326 |
scholarly article | Q13442814 |
P50 | author | Masakazu Takeuchi | Q91407325 |
Tomonori Oura | Q91802505 | ||
P2093 | author name string | Yukiko Onishi | |
Hitoshi Ishii | |||
P2860 | cites work | β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians | Q35572729 |
Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study | Q35754150 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. | Q37295993 | ||
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study | Q37295997 | ||
Real-life glycemic control in patients with type 2 diabetes treated with insulin therapy: A prospective, longitudinal cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT 9]). | Q38685102 | ||
Attitudes of patients and physicians to insulin therapy in Japan: an analysis of the Global Attitude of Patients and Physicians in Insulin Therapy study | Q39185926 | ||
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein | Q43054066 | ||
Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial | Q49576747 | ||
A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial | Q86505712 | ||
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes | Q90117073 | ||
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? | Q91198085 | ||
Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study | Q91407328 | ||
P433 | issue | 3 | |
P921 | main subject | type 2 diabetes | Q3025883 |
P304 | page(s) | 735-745 | |
P577 | publication date | 2020-01-29 | |
P1433 | published in | Diabetes Therapy | Q26853803 |
P1476 | title | Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen | |
P478 | volume | 11 |
Search more.